Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
CA24463V1013
Mon, 16.05.2022
Defence Therapeutics Inc.
Upcoming Investor Event:
Defense Therapeutics Inc. to present at digital International Investment
Forum (IIF)
On May 19, the IIF International Investment Forum will take place. At this
forum, Defense Therapeutics Inc. will also present its business model and
current business development.
Presentation slot:
Defense Therapeutics Inc. (ISIN: CA24 [ … ]
Tue, 15.02.2022
Defence Therapeutics Inc.
Einzigartig positioniert mit vielseitigem ACCUM(TM); Enormes
Aufwärtspotenzial; Die nächste Generation der Krebsbehandlung
- Proprietäre Plattformtechnologie mit nachweislich verbesserter
intrazellulärer Verabreichung. Fördert die Bereitstellung des
Zielprodukts ohne unspezifischen Protein-/Antigenabbau oder
[ … ]
Mon, 14.02.2022
Defence Therapeutics Inc.
Upcoming Investor Event:
Defence Therapeutics to present at digital International Investment Forum
(IIF)
On February 17, the IIF International Investment Forum will take place. At
this forum, Defence Therapeutics Inc. will also present its business model
and current business development.
Presentation slot:
Defence Therapeutics Inc.
08.00 am [ … ]
Thu, 10.02.2022
Defence Therapeutics Inc.
Uniquely Positioned with versatile ACCUM(TM); Enormous upside potential;
Next generation of cancer treatment
- Proprietary platform technology with proven enhanced intracellular
delivery. Promotes delivery of target product without non-specific
protein/antigen degradation or interference.
- Strong versatility of the Accum(TM) platf [ … ]
Mon, 24.01.2022
Defence Therapeutics Inc.
GBC Research Watchlist: Defence Therapeutics
Defence Therapeutics is led by Sebastien Plouffe. Mr. Plouffe has been a
successful Investment Advisor and CEO notably in the resource sector,
leading several junior companies to profitable exits. Mr. Plouffe is
supported by Dr. Moutih Rafei, VP R&D and Dr. Simon Beaudoin CTSO. Dr.
Rafei is a worl [ … ]
Mon, 06.12.2021
Defence Therapeutics Inc.
'We can work on any disease and adapt to any emergent pandemic such as the
one related to SARS-CoV2'
In its current letter to shareholders, Defence Therapeutics reports the
successful completion of its protein-based COVID vaccine (AccuVAC-PT001)
toxicology studies in non-rodent rabbit model. The AccuVAC-PT001 vaccine is
an injectable vaccine cap [ … ]